Date: 2015-05-05
Type of information: Establishment of a new subsidiary in the EU
Compound:
Company: Selvita (Poland)
Therapeutic area: Technology - Services
Type agreement: establishment of a new subsidiary in the EU
Action mechanism:
Disease:
Details: * On May 5, 2015, Selvita announced that the company is opening its first office in the United Kingdom. The office is based in Cambridge and will be responsible for supporting the ongoing projects for the customers from the UK and Northern Ireland, as well as seeking new collaboration opportunities in the area of integrated drug discovery services with pharma and biotech companies in the region. Selvita Ltd. will be focused on supporting and developing business relationships with local partners whereas Selvita’s laboratories remain in Krakow, Poland.
Selvita currently employs more than 230 professionals, mainly chemists and molecular biologists, 80 of whom have a PhD degree. The company offers integrated drug discovery services, medicinal chemistry, custom synthesis, in vitro biology services, protein production and analytical services. Selvita also conducts its own small-molecule research programs in oncology. Selvita’s client base includes many medium and large pharmaceutical and biotechnology companies from the USA, Western and Central Europe, Israel, Japan and Brazil. Selvita is listed on the Warsaw Stock Exchange.
Financial terms:
Latest news:
